Loading clinical trials...

EU Post-Market Registry to Collect Real-World Clinical Data on the Use of the Histolog Scanner. | Clinical Trials | Clareo Health

RECRUITING

EU Post-Market Registry to Collect Real-World Clinical Data on the Use of the Histolog Scanner.

A Prospective, Observational, Post-Market Registry to Collect Real-World Clinical Data on the Use of the Histolog Scanner in Multiple Disease Areas.

NCT07006090•SamanTree Medical SA

View on ClinicalTrials.gov

Summary

The goal of this observational study is to gather real-world evidence on the performance and safety of the Histolog® Scanner (HLS) when used as intended. HLS is a real-time ex-vivo tissue imaging device.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age ≥18 years old at the time of consenting
•Undergoing a surgery or a medical procedure with use of Histolog® Scanner
•Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria

•Active participation in a drug, device, or other medical intervention study that has not reached its primary endpoint at the time of consenting
•Patients under judicial protection, legal guardianship or curatorship.

Locations (1)

Royal Surrey County Hospital NHS Foundation Trust

Guildford, United Kingdom

Key Dates

Start Date

March 4, 2026

Primary Completion Date

March 1, 2036

Completion Date

April 1, 2036

Last Updated

March 5, 2026

Enrollment

5,000

ESTIMATED participants

Conditions

Adult Patients Undergoing a Surgery or a Medical Procedure With Use of Histolog® ScannerWhatever the Disease Area

Interventions

Histolog Scanner

DEVICE